Two physicians will discuss their research findings on SwabCap® during podium presentations at the upcoming annual meeting of the Association for Vascular Access (AVA).
SwabCap allowed for significant reductions of central-line-associated bloodstream infections (CLABSIs) at a meaningful cross-section of medical facilities, according to clinical research to be presented by Gregory Schears, MD, of Rochester, Minn.
Also presenting research in a podium talk will be Eddie Simpser, MD, FAAP, executive vice president and chief medical officer of St. Mary's Healthcare System for Children in Bayside, N.Y.
In addition to the doctors' talks, two scientific poster presentations at the conference will outline how the disinfection cap allowed for dramatic reductions in CLABSI rates. One of the posters is from Simpser's facility. The other is from St. Francis Hospital, in Columbus, Ga.
Schears' presentation will summarize a multi-site study in 12 hospitals that trialed the disinfection cap. Preliminary results showed SwabCap allowed for an average CLABSI rate reduction of 53 percent.
 Simpser will report data from a St. Mary's Hospital for Children initiative to reduce CLABSIs. The combination of SwabCap, a foam disc and IV line scrubbing sharply reduced the hospital's CLABSI rate.
Both talks will take place during Oral Abstract Presentation Session C113 on Tuesday, Oct. 4, from 5:30 p.m. to 6 p.m. in Room A3 at the conference site.
The AVA conference will also see the launch of a new product called SwabPack, which provides another option for making the cap available at the point of patient care. SwabPack contains 25 SwabCaps in a bar-coded plastic bag that can be hung from an IV pole.
SwabCap is a disinfectant cap that creates a closed system with its thread-cover seal. The FDA-cleared device passively disinfects the top and threads of needleless IV connectors, for use after an IV line is placed and between line accesses. A foam pad inside the sealed disinfectant cap releases 70% IPA that continually bathes the connector top and threads, thanks to the closed system and thread-cover seal. Compliance to infection control protocols is verified when the bright orange cap is observed in place.
At the AVA conference, Excelsior Medical, maker of SwabCap, will be at Booth 417 from Tuesday, Oct. 4 to Thursday, Oct. 6. Exhibit Hall hours are 11:15 a.m. to 1:30 p.m. all three days. The conference will be held Oct. 2-6 at the San Jose Convention Center in San Jose, Calif.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.